Mostly Markets
Subscribe
Stocks/Health Care/Health Care Technology

Veeva SystemsVEEV

Health Care Technology · Pleasanton, California · In the S&P 500
High qualityPricier than peers
$312.96+0.84%After hours: $312.00 (−0.31%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 9.2% over 1 year
Veeva Systems over 1 yearDaily close, $, to 30 Oct 2026
$150$200$250$300Nov2026MarMayJulSep$312.96$200NovMarJul$312.96
Source: Nasdaq daily closes
Market value$50.67B
Price to earnings51.2x
Forward P/E32.4x
Dividend yield–
Year to date+40.2%
One year+9.2%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$151.43$323.04

Quality and valuation

How Veeva Systems compares with other health care stocks. A description, not a recommendation.

Veeva Systems and 5 health care technology peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: stronger than mostValuation: pricier than most

A stronger business than most health care companies, priced above most of them.

Veeva Systems trades at 32.4 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew faster than the sector median: +16.5% vs +7.8%
  • Keeps more of each sale (gross margin): 75.0% vs 65.3%
  • More profitable (operating margin): 29.9% vs 13.3%
VEEV trades at 32.4x forward earnings, above the sector medianForward p/e, Health Care Technology peers
NVS17.0xAZN17.5xMRK18.1xUNH18.9xABBV19.6xJNJ25.1xVEEV32.4xLLY36.3xSector median 19.1xNVS17.0xAZN17.5xMRK18.1xUNH18.9xABBV19.6xJNJ25.1xVEEV32.4xLLY36.3xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 51.2x earnings, VEEV is pricier than its average since Sep 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
40x60xAverage 49.2x2025202651.2x40x60xAverage 49.2x2025202651.2x
Source: Nasdaq prices; SEC filings

Financials

From Veeva Systems's SEC filings, through the quarter ending 31 Jul 2026. Hover or tap a bar for its value.

Revenue grew 17.6% from a year earlierQuarterly revenue, $m, latest Q2 ’27
$0m$250m$500m$750mQ3 ’25Q1 ’26Q3 ’26$928mQ2 ’27$0m$500mQ3 ’25Q1 ’26Q3 ’26$928mQ2 ’27
Source: SEC filings
Growth sped up to +17.6% last quarterRevenue growth, year on year, %
0%5%10%15%Q3 ’25Q1 ’26Q3 ’2617.6%Q2 ’270%10%Q3 ’25Q1 ’26Q3 ’2617.6%Q2 ’27
Source: SEC filings
Operating margin was 29.6% last quarterOperating income as a share of revenue, %
0%10%20%30%Q3 ’25Q1 ’26Q3 ’2629.6%Q2 ’270%20%Q3 ’25Q1 ’26Q3 ’2629.6%Q2 ’27
Source: SEC filings
Diluted EPS was $1.66 last quarterQuarterly diluted earnings per share, $
$0.0$0.5$1.0$1.5Q3 ’25Q1 ’26Q3 ’26$1.66Q2 ’27$0$1Q3 ’25Q1 ’26Q3 ’26$1.66Q2 ’27
Source: SEC filings
Last 12 monthsVEEVSector median
Revenue growth+16.5%+7.8%
Gross margin75.0%65.3%
Operating margin29.9%13.3%
Price to earnings51.2x30.2x

Stories on Veeva Systems

We haven't written about Veeva Systems yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Health Care Technology, by market value.

CompanyPriceTodayYTDValue
LLYEli Lilly$1,417.54+3.19%+31.9%$1.33T
JNJJohnson & Johnson$273.20−0.73%+32.0%$658B
ABBVAbbVie$294.89+1.41%+29.1%$521B
MRKMerck$149.52+2.18%+42.0%$369B
UNHUnitedHealth$406.97−0.96%+23.3%$365B
NVSNovartis$160.79−0.19%+16.6%$327B
AZNAstraZeneca$186.65+7.02%+6.4%$290B
TMOThermo Fisher Scientific$697.00−1.72%+20.3%$258B